TP53 and non-small cell lung carcinoma: Dozens of other less common mutations have also been identified as oncogenic driver mutations of NSCLC, including BRCA2, SRC, DSP, RGL2, BTN3A2, and CCDC116, among others.64 In addition, loss-of-function mutations in tumor suppressor genes, such as TP53 and RB1, also frequently occur.32 Deeper studies are underway to further explore the therapeutic value of these pathogenic mutations.65